Johnson & Johnson (JNJ) Shares Bought by Old Mutual Global Investors UK Ltd.
Old Mutual Global Investors UK Ltd. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 15.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 178,038 shares of the company’s stock after buying an additional 24,191 shares during the period. Old Mutual Global Investors UK Ltd.’s holdings in Johnson & Johnson were worth $23,552,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Shine Investment Advisory Services Inc. purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $177,000. Ullmann Financial Group Inc. purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $186,000. Finally, Intercontinental Wealth Advisors LLC purchased a new position in shares of Johnson & Johnson during the second quarter valued at approximately $200,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
Johnson & Johnson (NYSE JNJ) traded up $1.39 during trading hours on Thursday, reaching $141.06. 5,591,700 shares of the company’s stock were exchanged, compared to its average volume of 5,876,467. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a fifty-two week low of $109.32 and a fifty-two week high of $144.35. The company has a market cap of $375,226.25, a P/E ratio of 19.56, a PEG ratio of 2.84 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
Several research firms have recently issued reports on JNJ. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 4th. Vetr lowered shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a report on Monday, September 18th. Stifel Nicolaus lifted their target price on shares of Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a report on Wednesday, October 18th. UBS restated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a report on Thursday, August 31st. Finally, Wells Fargo & Company upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $140.00 to $149.00 in a report on Monday, October 9th. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $144.59.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.